Back to results
US 2013/0172362 A1Published application
Imidazothiazole Derivatives Having Proline Ring Structure
AssigneeDaiichi Sankyo Company, Limited
InventorsKouichi Uoto, Yuuichi Sugimoto, Hiroyuki Naito, Masaki Miyazaki, Keisuke Yoshida, Masashi Aonuma
Life of this patent
Estimating the term…
Abstract
Compounds that inhibit interaction between murine double minute 2 (Mdm2) protein and p53 protein and that exhibit anti-tumor activity are provided. Compounds provided by the present disclosure include imidazothiazole derivatives that inhibit interaction between Mdm2 protein and p53 protein and exhibit anti-tumor activity.
Claims21
1-19. (canceled)
A method of treating cancer, comprising administering a compound according to formula (1):
- or a pharmaceutically acceptable salt thereof, to a patient,
- wherein
- Ar1 represents a phenyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a cyano group, and a C1-C6 alkyl group;
- Ar2 represents a phenyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a C1-C6 alkyl group, and a cyano group;
- or a pyridyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a C1-C6 alkyl group, and a cyano group;
- R1 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- or a C1-C6 alkanoyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, and a cyano group;
- a hydrogen atom;
- or a hydroxy group;
- R2 and R3 each independently represent a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- a carboxy group;
- or a hydrogen atom;
- or R2 and R3 may together form an oxo group;
- or R2 and R3 together with the carbon atoms to which R2 and R3 are respectively bonded may form a 3- to 5-membered saturated hydrocarbon ring in a spiro form;
- R4 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- R5 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- R6 represents a halogen atom or a hydrogen atom;
- and
- R7 represents a halogen atom.
16 more elements
A method of inhibiting cell growth, comprising administering a compound according to formula (1):
- or a pharmaceutically acceptable salt thereof, to a patient,
- wherein
- Ar1 represents a phenyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a cyano group, and a C1-C6 alkyl group;
- Ar2 represents a phenyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a C1-C6 alkyl group, and a cyano group;
- or a pyridyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a C1-C6 alkyl group, and a cyano group;
- R1 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- or a C1-C6 alkanoyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, and a cyano group;
- a hydrogen atom;
- or a hydroxy group;
- R2 and R3 each independently represent a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- a carboxy group;
- or a hydrogen atom;
- or R2 and R3 may together form an oxo group;
- or R2 and R3 together with the carbon atoms to which R2 and R3 are respectively bonded may form a 3- to 5-membered saturated hydrocarbon ring in a spiro form;
- R4 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- R5 represents a C1-C6 alkyl group optionally substituted with one or more substituents each independently selected from a halogen atom, a hydroxy group, a C1-C6 alkoxy group, a carbamoyl group, an amino group, a C1-C6 alkanoyl group, and a cyano group;
- R6 represents a halogen atom or a hydrogen atom;
- and
- R7 represents a halogen atom.
16 more elements
Dependencies are inferred from the claim text.